TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate. The TCRX average annual return since 2021 is shown above.
The Average Annual Return on the TCRX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TCRX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TCRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|